Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis
March 07, 2022 07:00 ET
|
Optinose, Inc.
XHANCE met both co-primary endpoints in the ReOpen1 trial, demonstrating statistically significant benefits on symptoms and CT scans in patients with chronic sinusitis There are no FDA-approved drug...
Optinose Announces Reporting Date for Fourth Quarter 2021 Financial Results
March 04, 2022 14:00 ET
|
Optinose, Inc.
Conference Call and Webcast to be held March 8, 2021 at 8:00 a.m. Eastern Time Company to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022 YARDLEY, Pa., March 04,...
Optinose Announces Appointment of Two New Members to Board of Directors
December 13, 2021 07:54 ET
|
Optinose, Inc.
YARDLEY, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Present at the Piper Sandler Virtual Healthcare Conference
November 23, 2021 07:00 ET
|
Optinose, Inc.
YARDLEY, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 18, 2021 16:30 ET
|
Optinose, Inc.
YARDLEY, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
Optinose Announces Closing of $46.0 Million Public Offering of Common Stock
November 18, 2021 14:00 ET
|
Optinose, Inc.
YARDLEY, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Pricing of Public Offering of Common Stock
November 16, 2021 08:02 ET
|
Optinose, Inc.
YARDLEY, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Proposed Public Offering of Common Stock
November 15, 2021 17:40 ET
|
Optinose, Inc.
YARDLEY, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Third Quarter 2021 Financial Results and Recent Operational Highlights
November 15, 2021 16:26 ET
|
Optinose, Inc.
Third quarter 2021 XHANCE net revenue of $22 million increased 41% compared to third quarter 2020 Third quarter 2021 XHANCE prescriptions increased 25% from third quarter 2020 Conference call and...
Optinose Announces Reporting Date for Third Quarter 2021 Financial Results
November 10, 2021 17:50 ET
|
Optinose, Inc.
Conference Call and Webcast to be held November 16, 2021 at 8:30 a.m. Eastern Time YARDLEY, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on...